NEW: We have just launched DHbriefs to offer a series of research briefs covering specific digital health market niches. Click here for more information.

Propeller, Novartis to develop add-on sensor for COPD patients

As patients use the Breezhaler™ inhaler, a patented capsule-based dry powder inhaler (DPI) for treatment of COPD, the new custom sensors will allow for passively recording and transmitting compliance data, better informing patients and their physicians of adherence and other treatment factors through the Propeller platform. Propeller has regulatory clearance to help patients and their physicians better understand asthma and COPD, and help to improve the symptoms and outcomes of these chronic respiratory diseases. The Novartis-Propeller partnership is focused on COPD in Europe.

Quotes


"We're excited to work with the team at Novartis to connect the Breezhaler™ device to the Propeller platform. The addition of this major respiratory franchise represents an important next step in our mission to bring valuable digital companions to everyone's respiratory treatments. With data from these medication sensors and interfaces, Propeller strengthens the relationships between patients and their physicians and helps them build effective treatment programs together."
David Van Sickle, CEO, Propeller Health
Links: Source

Leave a Reply

NEW: DHbriefs offers series of research briefs covering specific digital health market niches. Click here for more information.
Top